CRO Turk — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

CRO Turk is a private, revenue-generating CRO founded in 2005, headquartered in Ankara, Turkey, with additional offices in Dubai and Valencia. The company provides full-service clinical trial management, leveraging Turkey's modernized regulatory framework and high patient recruitment potential to serve international sponsors, primarily in oncology, rare diseases, and medical device studies. With a track record of ~100 projects, a 100% regulatory success rate, and expertise in Phase III and MedTech trials, CRO Turk has established itself as a key regional player connecting European clinical development with the Turkish and MENA markets.

OncologyCardiovascular

Technology Platform

Integrated CRO service platform specializing in Turkish and MENA clinical trials, built on deep local regulatory expertise (TİTCK, KVKK), a strategic site network for high-speed patient recruitment, and multiregional management capabilities for EU-MENA trials. Includes specialized MedTech/IVD MDR-compliant services.

Opportunities

Growing demand for cost-effective, fast-enrolling clinical trial sites in emerging markets like Turkey.

Increasing complexity of trials in oncology and rare diseases, and stringent new regulations for medical devices (MDR), creating need for specialized local CRO expertise.

Potential to expand as a preferred regional partner for European sponsors seeking integrated MENA trial management.

Risk Factors

High dependence on the stability and attractiveness of Turkey's regulatory and political environment.

Intense competition from both global full-service CROs and other local/regional providers.

Operational risk associated with maintaining a 100% regulatory success rate and EU-quality standards across a growing project portfolio.

Competitive Landscape

Competes with large global CROs (e.g., IQVIA, PPD, ICON) that have Turkish subsidiaries, as well as other local Turkish CROs. Differentiation is based on deep, specialized local regulatory and operational expertise, a focus on strategic partnership rather than scale, and a proven track record in late-phase and MedTech trials. Acts as a regional specialist versus global generalists.

More companies in Europe - Other →